ProMIS Neurosciences Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de ProMIS Neurosciences disminuyan a un ritmo anual de 6.7%, mientras que sus ingresos anuales crecerán a un ritmo de 85.7% por año. Se espera que el BPA crezca en un 11% al año.

Información clave

-6.7%

Tasa de crecimiento de los beneficios

11.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.5%
Tasa de crecimiento de los ingresos	58.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	26 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PMN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-52	N/A	N/A	2
12/31/2025	N/A	-34	N/A	N/A	2
12/31/2024	N/A	-28	N/A	N/A	2
12/31/2023	N/A	-13	-11	-11	N/A
9/30/2023	N/A	-17	-12	-12	N/A
6/30/2023	N/A	-20	-14	-14	N/A
3/31/2023	N/A	-21	-16	-16	N/A
12/31/2022	N/A	-18	-17	-17	N/A
9/30/2022	N/A	-13	-17	-17	N/A
6/30/2022	N/A	-8	-15	-15	N/A
3/31/2022	N/A	-6	-12	-12	N/A
12/31/2021	N/A	-10	-9	-9	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-8	-4	-4	N/A
3/31/2021	0	-9	-3	-3	N/A
12/31/2020	0	-4	-4	-3	N/A
9/30/2020	0	-5	-4	-4	N/A
6/30/2020	0	-5	-4	-4	N/A
3/31/2020	0	-5	-4	-4	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-8	-7	-7	N/A
3/31/2019	0	-8	-7	-7	N/A
12/31/2018	0	-7	-6	-6	N/A
9/30/2018	0	-6	-6	-6	N/A
6/30/2018	0	-5	-5	-5	N/A
3/31/2018	0	-5	-5	-5	N/A
12/31/2017	0	-5	-5	-5	N/A
9/30/2017	0	-5	N/A	-4	N/A
6/30/2017	0	-4	N/A	-3	N/A
3/31/2017	0	-3	N/A	-3	N/A
12/31/2016	0	-3	N/A	-2	N/A
9/30/2016	0	-2	N/A	-2	N/A
6/30/2016	0	-2	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A
6/30/2015	0	-2	N/A	-1	N/A
3/31/2015	0	-2	N/A	-1	N/A
12/31/2014	0	-2	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-2	N/A	-2	N/A
3/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	-2	N/A	-1	N/A
9/30/2013	0	-2	N/A	-1	N/A
6/30/2013	0	-2	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PMN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PMN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PMN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que PMN no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que PMN no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PMN se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ProMIS Neurosciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento